Mivuxin (Noradrenaline Tartrate)

Noradrenaline tartrate activates alpha‑adrenergic receptors on vascular smooth muscle, causing vasoconstriction and an increase in systemic vascular resistance. At higher concentrations it also stimulates beta‑1 receptors in the heart, modestly enhancing contractility and heart rate, together supporting blood pressure in shock states.

The dosing regimen for Mivuxin is individualized by the treating physician based on the patient's hemodynamic status, target blood pressure, and response to therapy. Clinicians typically start with a low infusion rate and titrate upward while monitoring arterial pressure and cardiac function.

Safety data for noradrenaline tartrate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Mivuxin (noradrenaline) is often considered the first‑line vasopressor for septic shock because of its potent alpha‑adrenergic activity and relatively predictable hemodynamic profile. Compared with agents such as dopamine or phenylephrine, noradrenaline provides stronger vasoconstriction with less tachyarrhythmia risk, making it a preferred choice in many critical‑care protocols.

Mivuxin should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before administration, the solution should be inspected for particulate matter and discoloration, and any unused portion should be discarded according to local regulations.

Mivuxin is given exclusively by intravenous infusion. It is typically prepared in a sterile diluent and administered through a calibrated infusion pump, allowing precise titration of the dose to achieve the desired blood pressure response while continuous hemodynamic monitoring is maintained.

The most serious adverse events include severe hypertension, myocardial ischemia or infarction, life‑threatening arrhythmias, and tissue necrosis at the infusion site due to extravasation. Prompt recognition and immediate management of these complications are essential to minimize patient harm.

Mivuxin is contraindicated in patients with known hypersensitivity to noradrenaline or any formulation component, and it should be avoided in individuals with pheochromocytoma or uncontrolled hypertension. Caution is also advised for patients receiving MAO inhibitors or ergot alkaloids due to the risk of extreme vasoconstriction.